Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapid switch from intravenous epoprostenol to intravenous Remodulin (treprostinil sodium) in patients with stable pulmonary arterial hypertension in the outpatient clinic: Safety, efficacy and treatment satisfaction

Trial Profile

Rapid switch from intravenous epoprostenol to intravenous Remodulin (treprostinil sodium) in patients with stable pulmonary arterial hypertension in the outpatient clinic: Safety, efficacy and treatment satisfaction

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Treprostinil (Primary) ; Epoprostenol
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top